These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 17220037)
21. Pharmacotherapy for obesity in menopausal women. Samat A; Rahim A; Barnett A Menopause Int; 2008 Jun; 14(2):57-62. PubMed ID: 18519266 [TBL] [Abstract][Full Text] [Related]
22. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Idelevich E; Kirch W; Schindler C Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):75-90. PubMed ID: 19144669 [TBL] [Abstract][Full Text] [Related]
23. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. Anghelescu I; Klawe C; Szegedi A J Clin Psychopharmacol; 2002 Oct; 22(5):521-4. PubMed ID: 12352278 [TBL] [Abstract][Full Text] [Related]
25. Drug treatment of the overweight patient. Bray GA; Ryan DH Gastroenterology; 2007 May; 132(6):2239-52. PubMed ID: 17498515 [TBL] [Abstract][Full Text] [Related]
26. What are the risks and the benefits of current and emerging weight-loss medications? Robinson JR; Niswender KD Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507 [TBL] [Abstract][Full Text] [Related]
27. The obesity pandemic--how did we get here? Malone M Ann Pharmacother; 2007 Sep; 41(9):1497-8. PubMed ID: 17652122 [No Abstract] [Full Text] [Related]
28. Emerging concepts in the medical and surgical treatment of obesity. Aylwin S; Al-Zaman Y Front Horm Res; 2008; 36():229-259. PubMed ID: 18230906 [TBL] [Abstract][Full Text] [Related]
29. [New therapeutic aspects for the control of risk factors in obesity]. Formiguera X; Sierra A Med Clin (Barc); 2007 Apr; 128(13):508-14. PubMed ID: 17419915 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy and surgery treatment for the severely obese adolescent. Woo T J Pediatr Health Care; 2009; 23(4):206-12; quiz 213-5. PubMed ID: 19559988 [No Abstract] [Full Text] [Related]
31. The new role of pharmacotherapy for weight reduction in obesity. Fernstrom MH; Fernstrom JD Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983 [TBL] [Abstract][Full Text] [Related]
34. FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus. Kachowski L; Over DR; Qiu K Am Fam Physician; 2012 Mar; 85(6):633-5. PubMed ID: 22534277 [No Abstract] [Full Text] [Related]
35. Current methods used for defining, measuring, and treating obesity. Moyad MA Semin Urol Oncol; 2001 Nov; 19(4):247-56. PubMed ID: 11769877 [TBL] [Abstract][Full Text] [Related]
36. [The endocannabinoid system and treatment of obesity]. Aronsen L Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201 [TBL] [Abstract][Full Text] [Related]
37. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
38. The endocannabinoid system as a target for obesity treatment. Aronne LJ; Pagotto U; Foster GD; Davis SN Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740 [TBL] [Abstract][Full Text] [Related]
39. [New drugs for the treatment of obesity]. Mustajoki P Duodecim; 1999; 115(20):2191, 2193-4. PubMed ID: 11973921 [No Abstract] [Full Text] [Related]
40. Drug treatment of obesity in the cardiovascular patient. Charakida M; Tousoulis D; Finer N Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]